138 related articles for article (PubMed ID: 15774740)
21. Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand.
Kawai T; Andrews D; Colvin RB; Sachs DH; Cosimi AB
Nat Med; 2000 Feb; 6(2):114. PubMed ID: 10655072
[No Abstract] [Full Text] [Related]
22. [Effects of gene transfer CTLA4-Ig and anti-CD154 monoclonal antibody on the rejection of rat islet xenografts].
Zhang J; Chen GH; Weng JP; Lu MQ; Yang Y; Cai CJ; Xu C; Li H
Zhonghua Wai Ke Za Zhi; 2008 Jan; 46(2):136-9. PubMed ID: 18509975
[TBL] [Abstract][Full Text] [Related]
23. Mouse opens door for study of autoimmune diseases.
Check E
Nature; 2004 Apr; 428(6985):786. PubMed ID: 15103338
[No Abstract] [Full Text] [Related]
24. Daclizumab treatment for multiple sclerosis.
Kim SE
Pharmacotherapy; 2009 Feb; 29(2):227-35. PubMed ID: 19170591
[TBL] [Abstract][Full Text] [Related]
25. [Monoclonal antibodies improve therapy of relapsing multiple sclerosis. Molecular basis and clinical results of anti-VLA4 (natalizumab) therapy].
Gold R; Hartung HP; Hohlfeld R
Dtsch Med Wochenschr; 2006 Jan; 131(1-2):31-4. PubMed ID: 16374741
[No Abstract] [Full Text] [Related]
26. 4D11: The Second Mouse?
Kirk AD
Am J Transplant; 2009 Aug; 9(8):1701-2. PubMed ID: 19660019
[No Abstract] [Full Text] [Related]
27. The curtain is drawn for both natalizumab and fingolimod (FTY720): a new era of multiple sclerosis therapy has arrived.
Weissert R
Expert Rev Neurother; 2006 Nov; 6(11):1587-90. PubMed ID: 17144774
[No Abstract] [Full Text] [Related]
28. [Natalizumab in multiple sclerosis: unclear patient benefits].
Schipper JP
Ned Tijdschr Geneeskd; 2007 Apr; 151(15):852-5. PubMed ID: 17472115
[TBL] [Abstract][Full Text] [Related]
29. Bedside to bench: betting on B cells in multiple sclerosis.
Link H
Nat Med; 2008 Jun; 14(6):615-6. PubMed ID: 18535578
[No Abstract] [Full Text] [Related]
30. FK506 and anti-CD40 ligand in peripheral nerve allotransplantation.
Brenner MJ; Mackinnon SE; Rickman SR; Jaramillo A; Tung TH; Hunter DA; Mohanakumar T
Restor Neurol Neurosci; 2005; 23(3-4):237-49. PubMed ID: 16082080
[TBL] [Abstract][Full Text] [Related]
31. Natalizumab: bound to rebound?
Schiess N; Calabresi PA
Neurology; 2009 Feb; 72(5):392-3. PubMed ID: 19188569
[No Abstract] [Full Text] [Related]
32. Autoimmune diseases. The B cell slayer.
Matthews R
Science; 2007 Nov; 318(5854):1232-3. PubMed ID: 18033858
[No Abstract] [Full Text] [Related]
33. Control of intestinal allograft rejection by FTY720 and costimulation blockade.
Yan S; Rodriguez-Barbosa JI; Pabst O; Beckmann JH; Brinkmann V; Förster R; Hoffmann MW
Transplant Proc; 2005; 37(1):114-5. PubMed ID: 15808565
[TBL] [Abstract][Full Text] [Related]
34. MS drug back on market under restricted program.
FDA Consum; 2006; 40(4):7. PubMed ID: 17243280
[No Abstract] [Full Text] [Related]
35. Is natalizumab overshooting its rebound?
Fox RJ; Kappos L
Neurology; 2008 Mar; 70(13 Pt 2):1073-4. PubMed ID: 18362270
[No Abstract] [Full Text] [Related]
36. Trends in the development of therapeutic anti-cytokine antibodies.
Reichert JM
Drug Discov Today; 2004 Apr; 9(8):348. PubMed ID: 15081960
[No Abstract] [Full Text] [Related]
37. New treatment, new hope for those with multiple sclerosis.
Bren L
FDA Consum; 2005; 39(2):10-7. PubMed ID: 16121419
[No Abstract] [Full Text] [Related]
38. Drug insight: using monoclonal antibodies to treat multiple sclerosis.
Hohlfeld R; Wekerle H
Nat Clin Pract Neurol; 2005 Nov; 1(1):34-44. PubMed ID: 16932490
[TBL] [Abstract][Full Text] [Related]
39. A novel fully human anti-CD40 monoclonal antibody, 4D11, for kidney transplantation in cynomolgus monkeys.
Imai A; Suzuki T; Sugitani A; Itoh T; Ueki S; Aoyagi T; Yamashita K; Taniguchi M; Takahashi N; Miura T; Shimamura T; Furukawa H; Todo S
Transplantation; 2007 Oct; 84(8):1020-8. PubMed ID: 17989608
[TBL] [Abstract][Full Text] [Related]
40. Natalizumab for the treatment of multiple sclerosis and Crohn's disease.
Keeley KA; Rivey MP; Allington DR
Ann Pharmacother; 2005 Nov; 39(11):1833-43. PubMed ID: 16219898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
